NetworkNewsBreaks – Silo Pharma Inc. (SILO) Brin
Post# of 138
(Total Views: 155)
Posted On: 05/23/2022 3:49:46 PM
NetworkNewsBreaks – Silo Pharma Inc. (SILO) Bringing Hope to Patients Suffering from Alzheimer’s and Potentially Other Ailments
Silo Pharma (OTCQB: SILO) is exploring the efficacy of ketamine in treating patients suffering from both Alzheimer’s and Parkinson’s disease. With more than 80% of Parkinson’s patients and 75% of Alzheimer’s patients experiencing dysphagia, difficulty or complete inability to swallow, last year, SILO entered into a joint venture with Zylö Therapeutics. Under the collaboration, the companies will explore an innovative technology – ZTI’s Z-pod transdermal technology – to develop a ketamine delivery system for those suffering from dysphagia. “In October 2021, Silo entered into a sponsored research agreement with Columbia University incorporating the work of Dr. Christine Ann Denny. According to a Silo Pharma news release, ‘Dr. Denny’s pioneering research into whether ketamine may improve memory retrieval, halt or even reverse the process of Alzheimer’s disease-related memory loss or cognitive aging, could have life-altering implications for people suffering with everything from Alzheimer’s to post-traumatic stress disorder (‘PTSD’),’” a recent article reads. Eris Weisblum, CEO of Silo Pharma said, “to be able to bring hope and possibly a therapeutic to patients suffering from Alzheimer’s disease (and potentially other ailments) is an exciting proposition for Silo Pharma.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Silo Pharma (OTCQB: SILO) is exploring the efficacy of ketamine in treating patients suffering from both Alzheimer’s and Parkinson’s disease. With more than 80% of Parkinson’s patients and 75% of Alzheimer’s patients experiencing dysphagia, difficulty or complete inability to swallow, last year, SILO entered into a joint venture with Zylö Therapeutics. Under the collaboration, the companies will explore an innovative technology – ZTI’s Z-pod transdermal technology – to develop a ketamine delivery system for those suffering from dysphagia. “In October 2021, Silo entered into a sponsored research agreement with Columbia University incorporating the work of Dr. Christine Ann Denny. According to a Silo Pharma news release, ‘Dr. Denny’s pioneering research into whether ketamine may improve memory retrieval, halt or even reverse the process of Alzheimer’s disease-related memory loss or cognitive aging, could have life-altering implications for people suffering with everything from Alzheimer’s to post-traumatic stress disorder (‘PTSD’),’” a recent article reads. Eris Weisblum, CEO of Silo Pharma said, “to be able to bring hope and possibly a therapeutic to patients suffering from Alzheimer’s disease (and potentially other ailments) is an exciting proposition for Silo Pharma.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)